ST百花(600721.SH)拟定增募资不逾4.3亿人币投资医药项目
ST百花(600721.SH)公布,公司拟以每股3.82元人民币(下同),向公司控股股东的全资子公司新疆华凌国际医疗产业发展有限公司,以及广西锦蓝投资管理中心和复思资产管理(北京)有限公司两名战略投资者非公开发行股票。
其中,新疆华凌国际医疗产业发展有限公司以现金认购此次非公开发行的股份,广西锦蓝投资管理中心和复思资产管理(北京)有限公司以其管理的契约式基金项下的财产认购此次非公开发行的股份。
此次募集资金总额不超过4.3亿元人民币,扣除发行费用後将用於MAH制度下药品的研发及产业化项目、小分子创新药物研发项目、多(月太)创新药及PDC药物研发项目和补充流动资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.